These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19940201)

  • 21. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
    Sela BA
    Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K; Riga M; Stefanadi E; Stefanadis C
    Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence.
    Scalera F; Borlak J; Beckmann B; Martens-Lobenhoffer J; Thum T; Täger M; Bode-Böger SM
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1816-22. PubMed ID: 15308550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
    Yin QF; Fu SH; He P; Xiong Y
    Atherosclerosis; 2007 Jan; 190(1):53-61. PubMed ID: 16533509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K; Mondon CE; Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The DDAH-ADMA-NOS pathway.
    Leiper JM
    Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADMA and oxidative stress.
    Sydow K; Münzel T
    Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
    Ferrigno A; Di Pasqua LG; Berardo C; Richelmi P; Vairetti M
    World J Gastroenterol; 2015 May; 21(17):5131-7. PubMed ID: 25954086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
    Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
    J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
    Stühlinger MC; Conci E; Haubner BJ; Stocker EM; Schwaighofer J; Cooke JP; Tsao PS; Pachinger O; Metzler B
    Cardiovasc Res; 2007 Jul; 75(2):417-25. PubMed ID: 17559823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
    Cable DG; Celotto AC; Evora PR; Schaff HV
    Med Sci Monit; 2009 Sep; 15(9):BR248-53. PubMed ID: 19721392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
    Böger RH
    Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Asymmetric dimethylarginine: predictor of cardiovascular diseases?].
    Németh B; Kustán P; Németh Á; Lenkey Z; Cziráki A; Kiss I; Sulyok E; Ajtay Z
    Orv Hetil; 2016 Mar; 157(13):483-7. PubMed ID: 26996894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
    Liu X; Xu X; Shang R; Chen Y
    Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
    Ghebremariam YT; LePendu P; Lee JC; Erlanson DA; Slaviero A; Shah NH; Leiper J; Cooke JP
    Circulation; 2013 Aug; 128(8):845-53. PubMed ID: 23825361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric dimethylarginine (ADMA) accelerates cell senescence.
    Bode-Böger SM; Scalera F; Martens-Lobenhoffer J
    Vasc Med; 2005 Jul; 10 Suppl 1():S65-71. PubMed ID: 16444871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.